News Snapshot:
Beijing, Nov 16 (EFE).- The first drug to treat Covid-19 of the several being developed in China could be approved for use in December and is based on the use of monoclonal antibodies capable of neutralizing the virus, state media reported Tuesday. The treatment is the result of a joint investigation by Tsinghua University, the People’s Hospital Number Three in Shenzhen and the Brii Biosciences company, headquartered in both China and the United States, according to the Global Times outlet. “The human body produces a large amount of antibodies, but not all of them have antiviral efficacy. Our research aims...
